Products for Research Use Only

PF-06465469

CAT: 0804-HY-108691-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-108691-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma[1][2].
CAS Number
1407966-77-1
UNSPSC
12352005
Hazard Statement
H315, H319, H335, H413
Target
Btk; CXCR; Itk; LAG-3; PD-1/PD-L1
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pf-06465469.html
Purity
99.48
Solubility
DMSO : 11 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=C(C(C)C)C(C)=C1)C2=CC=CC(C3=NN([C@H]4CN(C(C=C)=O)CCC4)C5=NC=NC(N)=C53)=C2
Molecular Formula
C30H33N7O2
Molecular Weight
523.63
Precautions
H315, H319, H335, H413
References & Citations
[1]Mamand S, et al. Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma. Sci Rep. 2018 Sep 21;8 (1) :14216.|[2]Fu Z, et al. IL-2-inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells. J Clin Invest. 2024 Nov 26;135 (4) :e178558.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported